קונבריזה

Country: Իսրայել

language: եբրայերեն

source: Ministry of Health

active_ingredient:

BAZEDOXIFENE AS ACETATE 20 MG

MAH:

NEOPHARM LTD

ATC_code:

G03XC02

pharmaceutical_form:

COATED TABLETS

administration_route:

PER OS

manufactured_by:

PFIZER IRELAND PHARMACEUTICALS

therapeutic_group:

BAZEDOXIFENE

therapeutic_indication:

CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

authorization_date:

2013-04-01